ABSTRACT
ABSTRACT In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).
Subject(s)
Humans , Female , Societies, Medical/trends , Menopause , Estrogen Replacement Therapy , Estrogen Replacement Therapy/adverse effects , Risk Factors , Estrogens/administration & dosageABSTRACT
The multiload 250 CU intrauterine device has been inserted in 298 women. Its effectiveness and the side effects connected with the use have been studied for a total of 3455 months of use. Two pregnancies and 5 expulsions have been observed while twelve devices were removed for pain and bleeding. The data compares quite favourably with those obtained with other IUDs.